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Abstract: An important stage in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) life 
cycle is the binding of the spike (S) protein to the angiotensin converting enzyme-2 (ACE2) host cell 
receptor. Therefore, to explore conserved features in spike protein dynamics and to identify 
potentially novel regions for drugging, we measured spike protein variability derived from 791 viral 
genomes and studied its properties by molecular dynamics (MD) simulation. The findings indicated 
that S2 subunit (heptad-repeat 1 (HR1), central helix (CH), and connector domain (CD) domains) 
showed low variability, low fluctuations in MD, and displayed a trimer cavity. By contrast, the 
receptor binding domain (RBD) domain, which is typically targeted in drug discovery programs, 
exhibits more sequence variability and flexibility. Interpretations from MD simulations suggest that 
the monomer form of spike protein is in constant motion showing transitions between an “up” and 
“down” state. In addition, the trimer cavity may function as a “bouncing spring” that may facilitate 
the homotrimer spike protein interactions with the ACE2 receptor. The feasibility of the trimer 
cavity as a potential drug target was examined by structure based virtual screening. Several hits 
were identified that have already been validated or suggested to inhibit the SARS-CoV-2 virus in 
published cell models. In particular, the data suggest an action mechanism for molecules including 
Chitosan and macrolides such as the mTOR (mammalian target of Rapamycin) pathway inhibitor 
Rapamycin. These findings identify a novel small molecule binding-site formed by the spike protein 
oligomer, that might assist in future drug discovery programs aimed at targeting the coronavirus (CoV) 
family of viruses. 
Keywords: SARS-CoV-2; coronavirus disease 2019 (COVID-19); spike glycoprotein; variability; 
molecular docking; molecular dynamics; inhibitors; trimer cavity; binding site 
 
J. Clin. Med. 2020, 9, 1473 2 of 18 
 
1. Introduction 
The global pandemic developing from December 2019 by a strain of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) can cause coronavirus disease 2019 (COVID-19) disease. This 
emergent variant adds to the additional coronavirus strains that can infect humans including human 
coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV-HKU1), SARS-CoV, human 
coronavirus 229E (HCoV-229E), human coronavirus NL63 (HCoV-NL63), and human coronavirus 
NL63 (HCoV-NL63) [1–6]. Coronaviruses (CoVs) are positive-sense, enveloped, single-stranded 
RNA viruses that are classified taxonomically as a family Coronavirdiae and order Nidovirales [4]. 
There are four genera of CoVs, including αCoV, βCoV, δCoV, and γCoV; most δCoVs and γCoVs 
target avians, whilst αCoVs and βCoVs infect rodents and bats [1,7,8]. Severe acute respiratory 
syndrome CoV (SARS-CoV) outbreaks have also emerged previously creating an epidemic [2,4,9–13]. 
Although the mortality of MERS-CoV, SARS-CoV, and SARS-CoV-2 is substantial, there are no 
preventative vaccines or drugs available to treat patients infected with the virus [9,11,12]. The current 
public health emergency of international concern (PHEIC) by the World Health Organization (WHO) 
has declared SARS-CoV-2 (COVID-19; a novel βCoV) as a pandemic threat. The data obtained from 
WHO (08/May/2020) suggest that the virus has caused 3,759,967 infections, 259,474 deaths, and it has 
affected over 200 countries. 
The Open Reading Frame 1ab (ORF1ab) of SARS-CoV-2 encodes for three proteins that are broadly 
recognized as drug targets, since they are key components for infections and disease progression: the 
SARS-CoV-2 protease [14,15], the RNA-dependent RNA Polymerase (RdRP) [14,16,17], and the SARS-
CoV-2 spike (S) glycoprotein [15,18–20]. The SARS-CoV-2 protease processes the polyproteins that are 
translated from the viral RNA, and it has been heavily studied using small molecules inhibitors [15]. To 
penetrate the host, the SARS-CoV-2 makes use of homotrimeric class I glycosylated fusion spike 
protein [18,21,22]. Fusion of the viral and host cell membranes is facilitated by the spike glycoprotein, 
which undergoes a significant conformational change upon fusion [18,21,22]. 
SARS-CoV-2 studies suggest [18,23,24] that the spike glycoprotein functions as a homotrimer. 
The recognition and subsequent fusion of the viral and cellular membranes are triggered by the S1 
subunit of the spike protein, which binds the host cell receptor; angiotensin converting enzyme-2 
(ACE2) [16,25–31]. Several insights from structural biology are consistent with the role for this 
domain in affecting the infection rate of the virus. This host–virus interaction is mediated by the 
receptor binding domain (RBD) domain from S1 subunit of SARS-CoV-2 spike glycoprotein that 
forms a hinge-like conformation [18,32], i.e., “down” and “up” states that represents the host cell 
receptor-inaccessible and receptor-accessible [18]. This receptor-accessible “up” conformation exists 
in a highly fluctuating state [33–36]. Binding to the host target destabilizes the pre-fusion homotrimer, 
which sheds off the S1 subunit, and allows for the transition of the S2 subunit to a highly stable 
postfusion conformation [18]. Interestingly, protein-mediated cell–cell fusion assays suggest that 
SARS-CoV-2 spike protein displays an elevated plasma membrane fusion capacity when compared 
to that of SARS-CoV [32,37]. 
Several studies have aimed to define the mechanism of binding of SARS-CoV-2 to the host cell 
receptor [38]. Molecular dynamics simulations of the spike (RBD)-ACE2 complex, over 10 ns indicated 
that spike(RBD)-ACE2 binding free energy for SARS-CoV-2 is better than for the SARS-CoV [39]. 
Similarly, other studies have shown that the SARS-CoV-2 spike protein has a better binding affinity 
to ACE2 at two different “up” angles of the RBD domain than the SARS-CoV [40]. Structural features 
at the spike-ACE2 interface suggest that residues Q493 and P499 from the spike RBD domain are 
responsible for maintaining protein–protein stability [41]. Using a virtual high-throughput screening 
approach, small-molecules have been identified that can interact with the RBD domain of SARS-CoV-2 
spike protein [42]. Natural compounds present in Curcuma sp., Citrus sp., Alpiniagalanga, and 
Caesalpiniasappan could also target the RBD domain of the SARS-CoV-2 spike glycoprotein, the 
protease domain (PD) from ACE2, and the SARS-CoV-2 protease [20]. A set of B cell and T cell 
epitopes derived from the spike and nucleocapsid proteins that map identically to SARS-CoV-2 
proteins, were identified as potential vaccine candidates [23]. 
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Applying an integrative, antiviral drug repurposing methodology, the interplay between the 
CoV–host interactome and drug targets in the human protein–protein interaction network have been 
defined [43]. Bioinformatics methodologies were used to identify neutralizing antibodies that might 
interact with interfaces formed by the spike glycoprotein and the ACE2 host cell receptor [24]. By 
targeting the RBD domain of the spike protein using docking experiments, Kanishka et al. identified 
small molecule inhibitors [44]. In the majority of studies, the most common strategy is focused on 
targeting the interface formed by SARS-CoV-2 spike glycoprotein and the ACE2 host cell receptor 
(i.e., spike(RBD)-ACE2). Currently, there are no robust drugs for wide-spread dissemination 
available against coronaviruses including; the SARS-CoV-2 virus. Due to the relatively rapid spread 
in the current outbreak and the relatively high mortality rate (3.5%), more rapid development of new 
or repurposed antiviral drugs is of high value. Although the majority of drug discovery programs 
target classically druggable enzymes encoded by the virus, such as the viral RNA polymerase 
inhibited by remdesivir [13,17,45], there is a paucity of information concerning the other regions of 
spike glycoprotein outwith the ACE2-binding domains, especially the domains interacting with the 
viral membrane. 
The SARS-CoV-2 spike protein is a homotrimer composed of three monomers (chains A, B, and 
C; Figure 1a). Each monomeric protein contains an N-terminal ACE2 binding domain (receptor 
binding domain; RBD), a central helix/heptad repeat, and a C-terminal region that interacts with the 
plasma membrane [18]. Homotrimer spike protein assembly from monomeric forms can be rate 
limiting in cells, suggesting a possible space for intervention on the viral life cycle [46]. Our current 
study focuses on understanding the variability of the trimer spike glycoprotein in SARS-CoV-2 with 
respect to the genomes from other coronavirus strains, and identifying the changes in the molecular 
properties due to conformational flexibility in the spike protein. The analysis suggests that residues 
in the S2 subunit are less variable compared to the other regions. In addition, the molecular dynamics 
simulations (MDS) identified that residues from the RBD domain obtained substantial flexibility 
which may be an obstacle in finding active hits. By contrast, residues in the S2 subunit (trimer cavity) 
showed the least flexibility representing a novel binding region for ligands. This information was 
used to identify potentially novel drug pockets or the active site regions specifically in the oligomeric 
SARS-CoV-2 spike glycoprotein. 
We performed MD simulations on the monomeric and trimeric form of the SARS-CoV-2 spike 
glycoprotein, and developed a virtual screening using a Food and Drug Administration (FDA) 
approved chemical library. We identified and focused on an apparent cavity formed by three 
subunits (the homotrimer), that our simulations suggest can mediate dynamic movements that mimic 
a “bouncing spring” or a “sarrus linkage (converting a circular motion to a linear motion or vice 
versa)” when interacting with the ACE2 host cell receptor. This motion might be important in the 
fusion of the virion and the host cell membrane. We hypothesized that such a cavity formed by three 
monomers or subunits of the spike protein (i.e., chains A, B, and C) might form an acceptor for small 
molecules, and we asked whether small molecules could be identified with a relatively high binding 
energy. We identified several known compounds with predicted binding energy of GBVI/WSA dG 
(Generalized-Born Volume Integral/Weighted Surface area) from −35 to −71 kcal/mol, some of which 
are already proposed for clinical trials including an mTOR (mammalian target of Rapamycin) 
pathway inhibitor, Sirolimus (Rapamycin; a macrolide type; NCT03901001 not yet recruiting) [47–49] 
and Ritonavir (open-label trial in hospitalized adults with severe COVID-19) [48,50–52]. A recent study 
that screened hundreds of approved molecules in a SARS-CoV-2 assay using artificial intelligence-
enabled phenomic assays [53], also identified Sirolimus (Rapamycin) as a promising candidate. In 
addition to the macrolides, one of the top hits we have identified, Chitosan, has a recently reported 
derivative inhibiting SARS-CoV-2 coronavirus replication in cell lines [54,55]. A previous study has 
also shown that the chitosan derivatives can interact with the spike protein and block its interaction 
with the host receptor [56]. Our data suggest a mechanism whereby Chitosan (and possibly its 
derivatives), as well as macrolide type molecules, might bind to a pocket formed by the spike protein 
trimer and provide a novel domain to focus on for future drug discovery projects. 
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Figure 1. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein structure and 
function. (a) The homotrimer spike glycoprotein (PDB ID. 6vsb) [18]. (b) Different domains of the 
spike protein that includes; signal sequence (SS), the N-terminal domain (NTD), receptor-binding 
domain (RBD), subdomain 1 and 2 (SD1&2), protease cleavage sites (S1/S2/S2′), fusion peptide (FP), 
heptad repeat 1 and 2 (HR1&2), central helix (CH), connector domain (CD), transmembrane domain 
(TM), and cytoplasmic tail (CT) [18,19]. (c) Receptor binding domain (RBD) illustrating the “up” or 
“open” (PDB ID. 6vsb [18]) and “down” or “closed” (PDB ID. 6vxx [31]) conformation. 
2. Material and Methods 
2.1. Bioinformatics Analysis of the SARS-CoV-2 Spike Variability 
A total of 791 viral genome sequences were downloaded from the Global Initiative on Sharing 
All Influenza Data platform (GISAID) [57], in order to define the evolutionary variability in different 
domains of the spike glycoprotein. Only genomes with high coverage and complete sequences were 
selected. Further filtering was applied to obtain complete sequences on the targeted domains which 
reduced the total number of strains to 768. Total protein sequences were acquired from 3 frame 
translation using the transeq tool from EMBOSS (European Molecular Biology Open Software Suite) 
package (version 6.5.7) (European Bioinformatics Institute (EMBL-EBI), Hinxton, Cambridge, UK) [58]. 
The amino acid chains from the spike glycoprotein were aligned to the reference protein (PDB ID. 
6vsb [18,59]) using MUSCLE [60]. Variations in the amino acid or the residue changes were scanned 
on the entire spike protein sequence, along with two areas of interest in the multiple alignment file, 
focusing on a subset of the S2 subunit (HR1, CH, and CD domains) and the RBD domain (Figure 1 
and Tables S1–S3). 
2.2. Structural Bioinformatics, Molecular Dynamics 
The cryo-EM (cryogenic electron microscopy) homotrimer structure of SARS-CoV-2 spike 
glycoprotein was retrieved from the Protein Data Bank database (http://www.rcsb.org/pdb; PDB ID. 
6vsb; Figure 1) [18,59]. In addition, the missing amino acid (residues range: 67–78, 96–98, 143–155, 
177–186, 247–260, 329–334, 444–448, 455–490, 501–502, 621–639, 673–686, 812–814, and 829–852) 
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coordinates in the structure of SARS-CoV-2 spike glycoprotein were built using the swissmodel 
(Figure 1) [61]. Molecular dynamics simulations were carried on the model systems as per the 
standardized pipelines [62–64] (detailed method explained in the supplementary materials; File S1). 
The GROMACS 4.6.5 [65] program (GROMACS; Groningen Machine for Chemical Simulations, 
University of Groningen, Groningen, The Netherlands) was used to perform MD calculations 
assigning the CHARMM27 forcefield [66]. We performed 100 ns molecular dynamics simulations on 
two systems: (i) The monomeric form and (ii) the homotrimer form of the spike protein. In our 
analysis of the MD simulations, the dynamics of the monomeric form of the spike protein serves as 
control to the homotrimer, which is the functional unit. Initially, the model systems were energy 
minimized, which provides a base-line model structure and resolves poorly-resolved conformations 
often found in crystal structures [13,18,62,67–70]. A simulation box of solvent atoms is then added to 
enhance simulation realism. Following that, using the NPT (number of particles (N), system pressure (P), 
and temperature (T); isobaric-isothermal) thermodynamic ensemble, equilibration of the systems was 
performed to adjust solvent molecules with counter ions in the simulation box [71]. These 
equilibrated systems were subsequently used to perform the final MD production runs for 100 ns, 
and results were analyzed using GROMACS [56], BIOVIA Discovery Studio (DassaultSystèmes, 
BIOVIA Corp., San Diego, CA, USA), Chimera, and visual molecular dynamics (VMD) tools [71–73]. 
2.3. In Silico Structure Based Virtual Screening 
Structure-based virtual screening (SBVS) is an application of in silico methods that identify 
promising lead molecules from chemical libraries or databases. These methods are computational 
counterparts of experimental biological evaluation methods, such as high-throughput screening (HTS). 
FDA approved drug libraries were retrieved from Target Molecule Corp. (TargetMol; 
www.targetmol.com) and Selleck Chemicals (Selleckchem; www.selleckchem.com) vendors. The 
SBVS against the SARS-CoV-2 spike glycoprotein was performed using the Molecular Operating 
Environment (MOE; Chemical Computing Group Inc., Montreal, QC, Canada) package [74,75]. 
Receptor–ligand binding or docking using the CHARMM27 forcefield [66] was evaluated using the 
GBVI/WSA ∆G scoring function [76]. The compounds showing best energies with the spike protein 
were selected for further analysis. GBVI/WSA ∆G is a forcefield based scoring function which 
determines the free energy of binding of the ligand from a given position [75]. In addition, we have 
also selected the compounds that showed comparatively stable interactions with the homotrimer 
spike protein. Applying the “Triangle Matcher”placement method, receptor–ligand docking was 
performed defining the receptor as rigid and ligands as flexible [74,75]. 
3. Results 
3.1. Investigating the SARS-CoV-2 Spike Glycoprotein Reveals a Cavity with Potential Utility as a Drug-
Binding Pocket 
3.1.1. Variability in the Spike Glycoprotein 
We were interested to define the evolutionary variance in the SARS-COV-2 spike protein. 
Understanding regions of high and low variance can identify domains that may be functionally 
conserved and potentially important to the virus life cycle, or those under positive evolutionary 
pressure whose selection might avoid the immune system. 
Examining the variability of the spike protein in SARS-CoV-2 and its different domains, a total 
of 791 genome viral sequences were retrieved from GISAID [57]. A global view of the mutation space 
of the virus is presented in Figure 2a, which represents the amino acid substitutions in bins of 10 
aminoacids across the spike glycoprotein. These hotspots of variation are mostly confined to the NTD 
and the RBD domains (Figure 1b and Figure 2b). We investigated the variability in the entire sequence 
of the spike protein, focusing on the regions that showed low-variability in the structure (Figure 2). 
By investigating the variations in the residue changes across the entire spike protein sequence 
or all the regions of lower variability (Figure 2a and Table S1), the S2 subunit exhibited the lowest 
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sequence variability (residue range: 816–1141; Figure 1b and Figure 2c). Moreover, previous studies 
have identified that the active site region for this spike protein is located in the RBD domain which 
interacts with the ACE2 host cell receptor [18,20,26,38–40,42,44]. Comparing the variability of the 
RBD domain and S2 subunit domains, the RBD domain was shown to contain more mutations in its 
region compared to the S2 subunit (HR1, CH, and CD) domains (Figure 2b,c, and Tables S1–S4). These 
data suggest that during mutation by natural selection, the viral-host “arms race” might operate more 
frequently on the RBD domain. By contrast, the S2 subunit conservation is suggestive of an important 
core function where mutations cannot be tolerated. These findings prompted our focus on the S2 
subunit as an important region to investigate for identifying potentially novel druggable pockets. 
 
Figure 2. Variability in the SARS-CoV-2 spike protein. (a) The heat map contains the amino acid 
substitutions for each position in the spike protein compared to the consensus sequence (wild-type) 
from the alignment of 791 SARS-CoV-2 strains from the Global Initiative on Sharing All Influenza 
Data (GISAID) database [57]. (b) Represents the previous variations over the spike protein structure, 
marking in red color the spots of variability. (c and d) Analysis of the amino acid substitutions in the 
receptor binding domain (RBD) domain and in the S2 subunit (HR1, CH, and CD domains), including 
a bar plot with the total number of changes for each position. 
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3.1.2. Molecular Properties and the Dynamics of the Spike Protein 
We next traced the dynamics of different domains in the spike protein using MD simulations 
(Figure 1b). The simulated model systems of the spike protein in the monomer and the homotrimer 
forms were first processed to check the stability of the protein. Stability of the simulated spike protein 
in both forms in the solvent environment was traced by RMSDs (root mean square deviation), a time 
dependent change in the non-hydrogen atoms (Figure 3a). The RMSD plots (Figure 3a) suggest that 
the trimer form of the spike protein is more stable compared to the monomer form. In addition, chain 
A in trimer has a higher RMSD (~2 Å) compared to the other two chains which is a consequence of 
the fact that the “up” (or ACE2-active) conformation [18] induces flexibility. Since the monomer form 
has a higher RMSDs compared to the trimer (Figure 3a), we performed independent triplicates (MDS 
was repeated three times) of MD simulation for the monomer form (Figure S1). The findings from 
these replicates indicate that the monomer form has a higher RMSD compared to the trimer spike 
protein (Figure 3a and Figure S1). 
The root mean square fluctuations (RMSF) were computed on the C  atoms of each residue from 
the spike protein, in order to trace their flexibility and thereby define the motions of different domains 
(Figure 3b). The RMSF findings in both forms (monomer and trimer) indicated that the amino acids 
in the RBD domain (residue range: 329–521) were highly fluctuating (Figure 1b and Figure 3b). In 
addition, the triplicate MD simulations of the monomer form, also suggests that the RBD domain has 
a higher RMSF in all three simulation replicates (Figure S1). These analyses correlate with previous 
studies [33–36,39]. Particularly, amino acids ranging from 470–490, responsible for interacting with 
the ACE2, that were highly fluctuating. Furthermore, examining other regions of the spike protein 
suggests that the S2 subunit domains (residue range: 850–1141; HR1, CH, and CD) showed the least 
fluctuations within the entire protein sequence (Figure 3b). This correlates with the cryo-EM studies 
performed on the spike protein; that the S2 subunit is more stable [18] compared to the RBD domain, 
and that this subunit is responsible for a highly stable postfusion conformation of the spike protein [18,32]. 
From the perspective of designing drugs, the more stable or less flexible a region is within a protein, 
the more accurately we can trace a better hit molecule. In the case of the spike protein, the RMSF 
findings guided us towards focusing on the S2 subunit (Figure 3b). 
Moreover, by tracing the residues involved in the H-bond interactions between two monomers 
(i.e., chains A-B, A-C, or B-C) of the homotrimer, we observed that the RBD domain residues were 
also involved in intermolecular interactions with each other and with high occupancy (%). This 
suggests that intermolecular interactions between chains in the homotrimer might equilibrate the 
spike protein, and might stimulate conversion from a “down” to “up” conformation of the RBD 
domain that interacts with the ACE2 receptor (Figure S2 and Table S5). 
The structural dynamics over the time course for spike protein in the monomer and the 
homotrimer form was monitored during MD simulations (Figure 3c,d). The monomeric spike protein 
in the solvent environment exhibited a movement from the “up” active state towards the “down” 
inactive state for the RBD domain (Figure 1c, Figure 3c, and Movie S1). These correlate with the 
previous findings that the RBD domain can form two different conformations, i.e., “down” and “up” 
states, which represents the host cell receptor-inaccessible and receptor-accessible, respectively [33–36]. 
The SARS-CoV-2 spike protein has a better binding affinity to the ACE2 receptor at two different 
“up” angles of the RBD domain compared to the SARS-CoV [40]. Figure 3c (and Movie S1) describes 
the conformational change in other regions of the spike protein, when the RBD domain moves 
towards an “up” to “down” state in the monomeric form. 
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Figure 3. Conformational dynamics of the SARS-CoV-2 spike glycoprotein. (a and b) RMSD and 
RMSF of the monomeric and trimeric forms. (c) The “up” and “down” state traced during the MD 
simulations of the monomeric form. (d) The conformation dynamics of homotrimer spike protein, as 
well as the highlighted cavity formed by the trimer state and its evolution over 100 ns of the MD 
simulation. RMSD, root mean square deviation; RMSF, root mean square fluctuations; MD, molecular 
dynamics. 
Figure 3d (and Movie S2) represents the dynamics of the homotrimer spike protein, suggesting 
that the RBD domain of chain A opens more widely in its “up” state. Domains HR1, CH, and CD 
close to the viral transmembrane exhibited the least movement (Figure 3d) during MD simulations. 
In addition, exploration of the structural orientation of these S2 subunit domains (Figure 3d and 
Movie S2) suggests that they form a large pocket or cavity using three chains (or monomers) from a 
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homotrimer spike protein. The slight movement observed in homotrimer during MD simulation of 
this cavity (Movies S1 and S2), and the structural orientation suggest that it could work as “bouncing 
spring” or “sarrus linkage”. One may postulate that, when the spike protein interacts with the ACE2 
receptor, this “bouncing spring” or “sarrus linkage” movement may be important in the fusion of the 
virion with the host membrane. Additionally, this cavity from the spike protein could work as a 
platform for the design or development of new drug leads against this protein (Figure 3d). Such 
molecules might alter the trimer stability upon viral entry or upon viral coat assembly. There have 
been several studies performed to design drugs specific for the SARS-CoV-2 spike protein [20,38–
40,42,44]; however, most of them are focused on the RBD domain. In addition, from our MD 
simulation and variability analysis (Figures 2 and 3), the RBD domain is highly flexible and variable, 
therefore, drugging this variable site may be an obstacle in finding active hit molecules. By targeting 
the less variable S2 region, such as the cavity formed by the homotrimer (Figure 2 and Figure 3d) we 
suggest that this might be a novel approach to develop small molecule drug leads. 
3.2. Potential Druggability of the Homotrimer Cavity 
We next investigated the targetability of the trimer cavity formed by the S2 subunit (HR1, CH, 
and CD domains) in the spike protein (Figures 2 and 3) using the MOE (Chemical Computing Group 
Inc.) package [74,75], before using it for high-throughput virtual screening (or SBVS) using a library 
of FDA approved drugs. The “Alpha Shapes” construction [75,77] geometric method was used to 
compute the possible residues that can be considered for ligand docking from this trimer cavity in 
the spike protein (Figure 4a). 
High-throughput virtual screening is a powerful computational approach that is increasingly 
being used in the drug discovery process, through the in silico identification of novel hits from large 
compound databases [78]. We applied the SBVS approach to dock the molecules to the trimer cavity 
and to check its feasibility as a target. Ligand binding to this cavity might reduce or increase the 
“bouncing spring” movement in the spike protein, as observed in MD simulations (Figure 3, Movies 
S1 and S2). This perturbation might affect its interactions with the host cell receptor or the hinge 
movement of the RBD domain. The compounds that exhibit a relatively high binding affinity towards 
the SARS-CoV-2 spike glycoprotein trimer cavity with a binding affinity −35 to −71 kcal/mol 
(GBVI/WSA dG) were recorded. From the list of ligands showing best binding, the compounds that 
were already validated or suggested to be/can be active against the SARS-CoV-2 virus includes: 
Chitosan [54–56], Rapamycin [47–49], Everolimus (RAD001) [49], Paclitaxel [79], Ritonavir [48,50–52], 
SelaMeerin (Selamectin) [80], and Danoprevir [52] (Table 1). 
Among these molecules Rapamycin and Everolimus drugs were previously identified as mTOR 
pathway inhibitors [47,50,81–83]. The antibacterial or antiparasitic drugs from the list are Chitosan [84] 
or SelaMeerin (Selamectin) [85], respectively. Paclitaxel, has been found to be previously target Bcl-2 
and microtubule associated functions [86,87]. In addition, the FDA approved drugs that target the 
protease are: Ritonavir [88] and Danoprevir (ITMN-191) [89]. 
By docking known drugs within the trimer cavity of spike protein, the relative selectivity of the 
cavity suggests that the majority of higher-affinity drugs will have a molecular weight (MW) ≥ ~700 g/mol 
(Table 1 and Figure S3). However, this is with the certainty that compounds with high MW can form 
more interactions with the spike protein, in addition, our finding highlights the possibility that the 
trimer cavity can occupy large ligands deep inside the binding pocket (Figure 4a). Particularly, a 
specific class of ligands (mostly macrolide type) were found to exhibit a better fit to the trimer cavity 
(Figure 4a); for example, Rapamycin [47–49], Everolimus (RAD001) [49], Paclitaxel [79], and 
SelaMeerin (Selamectin) [80] (Figure 4a). The intermolecular interactions between the spike protein 
and the compounds suggest that residues from all three monomers (chains A, B, and C) are actively 
involved in binding to the drugs. In addition, placement of the compounds inside the trimer cavity 
suggests that they make use of the pocket space (forming different conformation) to form stable 
interactions with the spike protein (Figure 4a). 
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Figure 4. Targeting different pockets of the SARS-CoV-2 spike protein. (a) The homotrimer cavity 
from the SARS-CoV-2 spike glycoprotein bound to known compounds. (b) The ligands that were 
found interacting with the homotrimer cavity with high binding affinity were also docked with an 
interface formed by the spike proteins (RBD domain; PDB ID. 6lzg [90]) that interact with the ACE2 
receptor. SBVS, structure-based virtual screening. 
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Table 1. The list of compounds showing the highest binding affinity to the trimer cavity from the 
spike protein, and the compounds that are already validated or suggested to be/can be active against 
the SARS-CoV-2 virus *. 
Compounds Against SARS-
CoV-2 
GBVI/WSA dG (kcal/mol) 
MW 
g/mol 
Previous Target Trimer 
Cavity 
RBD 
Domain 
Chitosan [54–56] −67.49 −37.30 161.16 * Antibacterial [84] 
Rapamycin (Sirolimus) [47–49] −49.28 −25.81 914.17 mTOR [47] 
Paclitaxel [79] −45.84 −32.42 853.92 
Bcl-2, Microtubule Associated 
[86,87] 
SelaMeerin (Selamectin) [80] −44.24 −32.35 769.96 Antiparasitic [85] 
Everolimus (RAD001) [49] −41.80 0.29 958.22 mTOR [83] 
Ritonavir [48,50–52] −37.92 −24.11 720.94 HIV Protease [88] 
Danoprevir (ITMN-191) [52] −35.09 −30.80 731.83 Proteasome, HCV, Protease [89] 
* Drugs in this list are in need of further clinical validation. MW for the monomer Chitosan compound 
is 161.16 g/mol, and for the entire Chitosan molecule is 1526.46 g/mol. GBVI/WSA, Generalized-Born 
Volume Integral/Weighted Surface area; mTOR, mammalian target of Rapamycin; HIV, human 
immunodeficiency viruses; HCV, hepatitis C virus; RBD, receptor binding domain; MW, molecular 
weight. 
In order to check the selectivity of these ligands to the trimer cavity, we docked this same subset 
(Table 1) with the RBD domain of the viral spike protein (Figure 4b; PDB ID. 6lzg [90]). The RBD 
domain is involved in interacting with the ACE2 host cell receptor [16,26,30,38–42,90,91]. The docking 
suggests that all compounds from Table 1 have better binding affinity to the trimer cavity compared 
to that of the RBD domain. In addition, Chitosan [54–56,84] (a linear polysaccharide; −37.29 kcal/mol) 
could form a linear conformation in its structure when binding tothe RBD domain (Figure 4b and 
Table 1), whilst the same ligand (due to its molecular structural nature) can form a slightly folded 
shape (as shown in 2d-diagram; Figure 4a) within the trimer cavity. By contrast, Everolimus [49] (a 
macrolide type) exhibits high affinity for the trimer pocket, and very little selectivity for the RBD 
domain (Table 1). Moreover, ligands (Figure 4b) that interact with the RBD domain overlap with the 
region bound by CR3022 (a neutralizing antibody isolated from a convalescent SARS patient that, 
interacts with the receptor binding domain of the SARS-CoV-2 spike protein [92]). 
4. Discussion 
The SARS-CoV-2 virus causing COVID-19 disease uses the fusion spike glycoprotein to 
penetrate into the host cell, and therefore a detailed understanding of this protein forms a critical 
intervention point in the viral life-cycle. We interrogated the spike protein with a diversity of 
computational approaches. First, the variability in spike protein from 791 different viral genome 
sequences was evaluated. Residues in the S2 subunit (residue range: 816–1141; HR1, CH, and CD 
domains) were found to be less evolutionarily variable compared to other regions or domains. By 
contrast, residues H49Y, Q239K, V367F, V483A, S943P, K986P, and V987P were found to be the most 
common amino acid substitutions in the spike protein from related viruses. Secondly, MD 
simulations revealed that residues in RBD domain (residue range: 329–521) were more flexible 
compared to residues in the S2 subunit, making it more complicated for drug design strategies. An 
examination of less variable regions revealed that the HR1, CH, and CD domains (S2 subunit) located 
close to the viral transmembrane formed a large cavity or pocket that is formed from three spike 
monomers. The MD simulation traced an “up” active state and a “down” inactive state of the spike 
protein in its monomer form. Slight movement of the trimer cavity within this structural orientation 
suggests that it could work as “bouncing spring” or “sarrus linkage” when interacting with the host 
cell receptor. 
The conversion between “up” and “down” states in the monomer form of spike protein using 
the in silico methods is defined by the MD field to be relatively fast. Nevertheless, there are different 
structural isoforms that have been identified on the spike protein using different experimental 
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methods or virus strains. This indicates that, although conversion may be quick, there are structural 
endpoints which are “stable”. Using the recent cryo-EM structure of the SARS-CoV-2 spike protein [18]; 
an asymmetric hinge-like movement was observed in only one of the three RBD domains in the S1 
subunit, which was also observed in MERS-CoV and SARS-CoV [33,34]. However, there are also 
other structures where all three RBD domains are in the “up” or “down” conformation 
[18,31,33,34,40]. These data suggest a physiological relevance due to heterogeneous protein 
conformational dynamics. For example, asymmetric conformational flexibility might have a 
functional role, perhaps in evading the exposure of B-cell epitopes (only one RBD domain is in the 
“up” conformation) and/or optimized interaction with the ACE2 receptor depending on virus strain. 
In addition, because of the “bouncing spring” mechanism (communication between the trimer pocket 
and the RBD domain conformation), it is possible that these different spike protein conformational 
isoforms provide another avenue to develop drug discovery programs that exploit and/or circumvent 
these dynamics. 
Our investigation into the genomic variation within virus strains, as well as our findings from 
the MD simulations, identified a conserved trimer cavity or pocket formed by the S2 subunit in the 
spike protein. These findings suggest that a novel target, “the trimer cavity formed by spike protein 
oligomerization”, may be suitable to manipulate viruses of this class. Targeting the trimer pocket 
might identify a new functional class of drugs against this protein. Applying the SBVS approach, we 
docked drug libraries against the trimer cavity with the hypothesis that such a ligand might perturb 
the predicted “bouncing spring” movement and the homotrimer formation. Protein–ligand docking 
identified severalhits that have already been published or proposed to inhibit the SARS-CoV-2 virus 
in cell systems. For example, our studies suggest an action mechanism for molecules such as Chitosan 
and macrolide types (e.g., Rapamycin). 
Based on the sequence variability of the coronavirus, including our findings from MD 
simulations of the spike protein, a conserved trimer cavity (HR1, CH, and CD domains) is a feature 
of the spike protein in most coronaviruses. Consistent with this, previous work has shown that the 
molecule EK1 exhibited potent inhibitory activity against all human coronaviruses (hCoVs) tested 
through binding to the C-terminal HR1 domain [37]. Additionally, the “up” and “down” 
conformations of RBD domain observed during MD simulations, supports that concept that the spike 
protein can also be a target of a possible IgG therapeutic [92]. From the list of the top compounds 
identified that dock into the trimer cavity, some of them have already been validated or suggested as 
SARS-CoV-2 virus inhibitors in cells, including; a Chitosan derivative [54–56], Rapamycin [47–49], 
Everolimus (RAD001) [49], Paclitaxel [79], Ritonavir [48,50–52], SelaMeerin (Selamectin) [80], and 
Danoprevir [52]. Among these, a modified polymeric version of the Chitosan drug (a top hit in our 
analysis) was recently shown to inhibit CoV replication with evidence that the molecule inhibits the 
binding of the viral spike protein to the host ACE2 receptor [54–56]. The protein–protein interaction 
map or the network-based methodologies [14,43] suggest that Sirolimus (Rapamycin) emerges as a 
common potential drug lead for repurposing against COVID-19. This Rapamycin (mTOR inhibitor) 
drug was found previously to disrupt LARP1 (La-related protein 1) and mTORC1 (mammalian target 
of rapamycin complex 1) binding, and has been shown to reduce MERS infection by ~60% in vitro [47]. 
The postulated geroprotectors, such as Sirolimus (Rapamycin) and its close derivative, the rapalog 
Everolimus (RAD001), decreased infection rates in a small sample of elderly patients [49]. 
Moreover, the drugs Sirolimus (Rapamycin) and Ritonavir are currently in clinical trials for 
repurposing against COVID-19 [48,50,51]. Sirolimus (Rapamycin) is registered in a clinical trial 
(NCT03901001 not yet recruiting) designed to evaluate adjunctive use of Sirolimus (Rapamycin) and 
Oseltamivir in patients hospitalized with influenza [47,48]. Ritonavir, a HIV protease inhibitor is in 
an open-label trial in hospitalized adults with severe COVID-19 [48,51]. The data from this small-
sample clinical study showed that Danoprevir boosted by Ritonavir is safe and well tolerated in all 
patients [52]. Selamectin is a potential drug for treating COVID-2019 found active against the 
pangolin coronavirus GX_P2V, a workable model for SARS-CoV-2 research [80]. The antitumor drug 
Paclitaxel increases cellular methylglyoxal to virucidal levels, providing a rationale for repurposing 
Doxorubicin and Paclitaxel for COVID-19 treatment [79]. Nevertheless, whether the hit molecules we 
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have identified that dock into the trimer cavity and impact on the virus life cycle requires orthogonal 
validation. We hope the findings of our study can help to understand the function of the highly 
conserved spike protein trimer cavity in the SARS-CoV-2 viral life cycle, as well as provide a novel 
approach to target this class of infectious disease by the examination of spike protein trimer stability 
and/or assembly. 
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bond (H-bond) interactions between three monomers (i.e., chains A-B, A-C, and B-C) of the homotrimer spike 
protein traced during the MD simulations. In this table, the interaction pairs with donor or acceptor are 
mentioned, and residues showing occupancy (%) ≥10 % are considered; Figure S1: Triplicates of the MD 
simulations (or MD repeated three times) for the monomeric form of the SARS-CoV-2 spike protein. The plots 
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S2: The intermolecular H-bond (hydrogen bond) interactions formed between three monomers (i.e., chains A-B, 
A-C, and B-C) of the homotrimer spike protein traced during the MD simulations, Figure S3: Correlation 
between the binding affinity (GBVI/WSA; kcal/mol) and molecular weight (MW; g/mol) of the compounds 
showing good or the best binding with the trimer cavity of the SARS-CoV-2 spike protein; Movie S1: The 
conformation dynamics of the monomeric form of the spike protein. This movie is generated using Chimera, 
taking into consideration the spike protein coordinates from 1 ns and 100 ns of the MD simulation, Movie S2: 
The conformation dynamics of the homotrimer spike protein observed during the MD simulations, focusing on 
the homotrimer cavity. The movie is generated using Chimera, taking into consideration spike protein 
coordinates from 1 ns and the average structure generated from the entire MD simulation (1-100 ns). 
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